FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage

PHASE2RecruitingINTERVENTIONAL
Enrollment

524

Participants

Timeline

Start Date

August 13, 2025

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2030

Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
DRUG

Fludrocortisone

small white tablet containing 100mcg of fludrocortsone

DRUG

Placebo

Matched placebo tablet,

Trial Locations (16)

1023

NOT_YET_RECRUITING

Auckland City Hospital, Auckland

2031

NOT_YET_RECRUITING

Prince of Wales Hospital, Randwick

2042

NOT_YET_RECRUITING

John Hunter Hospital, New Lambton Heights

2065

NOT_YET_RECRUITING

Royal North Shore Hospital, St Leonards

2145

NOT_YET_RECRUITING

Westmead Hospital, Westmead

2521

NOT_YET_RECRUITING

Wollongong Hospital, Wollongong

2747

RECRUITING

Nepean Hospital, Penrith

3044

NOT_YET_RECRUITING

The Alfred Hospital, Melbourne

3065

NOT_YET_RECRUITING

St Vincent's Hospital (Melbourne), Fitzroy

3168

NOT_YET_RECRUITING

Monash Medical Centre, Clayton

4029

NOT_YET_RECRUITING

Royal Brisbane Women's Hospital, Brisbane

4102

NOT_YET_RECRUITING

Princess Alexandra Hospital, Woolloongabba

4215

RECRUITING

Gold Coast University Hospital, Gold Coast

4814

NOT_YET_RECRUITING

Townsville Hospital, Townsville

6011

NOT_YET_RECRUITING

Wellington Hospital, Wellington

7000

NOT_YET_RECRUITING

Royal Hobart Hospital, Hobart

All Listed Sponsors
lead

The George Institute

OTHER

NCT06409364 - FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage | Biotech Hunter | Biotech Hunter